Pharmacology Grants

The J. Worth Estes Prize

This award was established in honor of J. Worth Estes, M.D., in recognition of his many years of invaluable contributions to the American Association for the History of Medicine and to scholarship in the history of medicine. The award is made annually for the best published paper in the history of pharmacology during the previous two years, whether appearing in a journal or a book collection of papers. The choice of topic reflects Worth Estes’s long tenure as Professor of 700 news and events Bull. Hist. Med., 2008, 82 Pharmacology and Experimental Therapeutics at Boston University and his own scholarship in the history of pharmacology.

For the purpose of this award, the history of pharmacology will be defined broadly to include ancient and traditional materia medica, folk medicines, herbal medicines, the pharmaceuticals and medications of the modern era, pharmaceutics, and the like. It shall encompass the discovery of medicaments, basic investigations about them, their characteristics and properties, their preparation and marketing, and their therapeutic applications.

While the committee will be monitoring relevant journals and books where such papers might appear, they welcome nominations of papers that would be eligible for consideration. The nomination should consist of a letter citing the work nominated along with a copy of the paper. For the current award, candidate papers will be those published in 2007 and
2008. Papers in languages other than English should be accompanied by a translation or detailed precis.

Nominations should be directed to the Chair of the Committee,
Jan McTavish, Alcorn State University,
Department of Social Sciences,
Lorman, MS, 39096
mctavish@alcorn.edu

Nominations must be received by the Committee Chair by 15 January 2009.
The award will be presented at the annual meeting of the AAHM in Cleveland, Ohio, 23–26 April 2009. As a result of a generous contribution in honor of Worth Estes from a member of the Association, the award will be accompanied by a $500 check

Paul M. Vanhoutte Distinguished Lectureship in Vascular Pharmacology

Deadline for submission of nominations for the 2010 Paul M. Vanhoutte Distinguished Lectureship in Vascular Pharmacology is September 15, 2009

The Paul M. Vanhoutte Award in Vascular Pharmacology was established to honor Dr. Vanhoutte’s lifelong scientific contributions to our better understanding and appreciation of the importance of endothelial cells and vascular smooth muscle function in health and disease and for his mentoring of countless prominent endothelial and vascular biologists and pharmacologists.

The Paul M. Vanhoutte Award is a biennial award, consisting an honorarium of $1,000, a custom-designed crystal bowl depicting the named Lectureship, and up to $2,000 travel expenses including registration to the annual spring ASPET meeting. A recipient will be selected and invited to deliver a state-of-the-art lecture on recent advances in vascular biology and pharmacology at the spring ASPET meeting (Division’s programming session). The presentation of his/her research should be of broad interest and contribute to the growth of the Cardiovascular Pharmacology Division.

There are no restrictions on institutional affiliation, nationality, or age of the candidate, but the recipient must be a member of the ASPET. Nominations must be made by a member of the ASPET, and no member may nominate more than one candidate per year. Final selection of the recipient will be made by the Award Committee of the Division for Cardiovascular Pharmacology.

Nominations should consist of not more than five letters from nominators describing the contributions to vascular biology and pharmacology of the candidate that make him/her eligible for this Award and listing of his/her major contributions, together with a complete curriculum vitae. To ensure consideration, all information must be submitted electronically to: Margie Arkin (markin@aspet.org), American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995 no later than September 15, 2009.

American Society of Pharmacognosy Undergraduate Research Award

The ASP Undergraduate Research Awards consist of a stipend of $2,000 to the student and $500 to the advisor to help defray the costs of the research. There are no limitations on the type of research to be conducted other than that it should be in the area of natural products. Applications should be submitted via email. Applications for the Undergraduate Research Award must be received by December 15, 2008 (usually February 15 in other years) and consist of the following

· An outline of the research to be conducted, written by the student applicant. This should include a statement of the problem and the goal(s) of the research, and a brief discussion of the methodology. This outline, with pertinent references, should not be longer than four double-spaced, typed pages.

· A transcript of all college work attempted.

· A curriculum vitae, including contact information and email address (upon receipt of a completed application, a confirming receipt will be sent by email).

· A letter of agreement by the faculty advisor (a member of the American Society of Pharmacognosy) for the project, indicating a willingness to supervise the project, and provide the facilities and equipment for the conduct of the project. The letter should also include a statement about the student's academic performance and suitability to perform the work proposed.

Although not an absolute condition of the awards, students selected are highly encouraged to submit results of their research for presentation at an annual meeting of the ASP. Funds, as available, will be offered to these Award winners to help support their travel and other costs associated with attendance at the annual meeting.

Applications for the student and member grants and awards can be sent to:
Philip Proteau (phil.proteau@oregonstate.edu), Chair

American Society of Pharmacognosy Student Research Award

ASP Student Research Awards are designed to recognize outstanding research in the general area of natural products. The competition is open to all graduate and undergraduate students working with a member of the ASP. Students should submit cover letter that includes contact information including email address and a research paper describing his/her own work in the area of natural products. The research paper should conform in general to the format of the Journal of Natural Products. Up to two awards will be made in any year. The award will consist of a $500 cash gift and up to $1000 assistance with expenses to present the paper at the annual meeting of the ASP (restricted to meetings held in continental North America and Hawaii). If applicants for the Student Research Award who are working in colleges or schools of pharmacy provide the required certification letter from the student's Dean or Registrar, they will be considered automatically for the Kilmer Prize. The deadline for submission of the research paper is December 15th, 2008 (usually February 15th of each year). Applications should be submitted via email. Applications submitted electronically will receive a confirmation of receipt by email.

Applications for the student and member grants and awards can be sent to:
Philip Proteau (phil.proteau@oregonstate.edu), Chair

sanofi-aventis U.S. Award
ASM's premier award in antimicrobial chemotherapy research; it stimulates research and honors outstanding accomplishment in antimicrobial chemotherapy. Nominees must be actively engaged in research involving development of new agents, investigation of antimicrobial action or resistance to antimicrobial agents, and/or the pharmacology, toxicology or clinical use of those agents. Nominees must not have served on the ICAAC Program Committee within the past two years.

Award: A cash prize of $20,000, a commemorative medal, and travel to ICAAC where the laureate delivers the sanofi-aventis U.S. Award Lecture. ASM awards are granted at the discretion of award selection committees and may not be awarded every year.

Deadline: April 1.

Nominations: Nominations will be considered without updating for three years; self-nominations will not be accepted. Nominations must consist of the following:

*Curriculum vitae, including a list of publications.

*Letter of nomination. Describe the nominee's outstanding accomplishment in antimicrobial chemotherapy, including a list of the ten most relevant publications to the award.

*Letters of support. Two letters of support should come from two people, other than the nominator, who are familiar with the nominee's accomplishments.

No more than one of the three letters may be from the nominee's institution or the same institution.
Email all nomination components to awards@asmusa.org.

Therapeutics Development Initiative 2009
Pre-Proposal Receipt Date: January 20, 2009 – 6:00pm US ET

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announces the launch of its Therapeutics Development Initiative (TDI) for Spring 2009, a funding mechanism to support and stimulate preclinical Parkinson’s disease research at for-profit institutions. This funding program seeks to support preclinical development of Parkinson’s disease therapies which have the potential for fundamentally altering disease course and/or improving treatment of symptoms above and beyond current standards of care. Proposals must focus on key and critical preclinical studies necessary for developing, optimizing and evaluating therapeutic strategies that if successful can move into human testing.
Responsibility for the planning, direction, and execution of the proposed project will be solely that of the principal investigator who must be an employee of a for-profit entity. Academic investigators may have an advisory role in the project, but the operational and strategic ownership of the project must reside within the company.

Investigators may seek up to two years of funding for preclinical development and testing of novel therapeutic approaches for the treatment or prevention of Parkinson’s disease.

Please note that pre-proposals are mandatory and will be used to evaluate your proposal’s fit with the stated aims and review criteria of the RFP. All pre-proposals received in response to this program will be subjected to a triage process and only those pre-proposals deemed to be of suitable scientific merit will be invited to submit a full application.

MJFF employs an expedited, abbreviated granting mechanism to accelerate discoveries and ultimately translate findings to PD patients more quickly.

Conference Call
MJFF will hold a 45 minute long conference call on December 16, 2008 at 12:00 PM U.S. Eastern Time to clarify and explain the Therapeutics Development Initiative 2009 program and to answer applicants' questions. To participate in this call, you must RSVP via email to conferencecalls@michaeljfox.org. Participants will receive a reply with call-in details.

While there are no restrictions as to the specific approaches to be studied under this RFP,
successful applications are most likely to focus on at least one of the following categories:
o Neuroprotective strategies focused on slowing or preventing the process of neuronal
death.
o Neuroregenerative strategies to restore or replace neuronal function.
o Novel drug delivery mechanisms and/or surgical procedures.
o Innovative therapeutic approaches to treat the motor and non-motor symptoms of PD,
including cognitive dysfunction, autonomic dysfunction, sleep disorders, or depression
among others.
o Therapeutic approaches to alleviate complications of PD treatment including dyskinesias,
etc.

If you would like to contact the Foundation, please call toll-free at 1-800-708-7644, or contact us by regular mail at the following address:

The Michael J. Fox Foundation for Parkinson's Research
Church Street Station
P.O. Box 780
New York, NY 10008-0780

Potamkin Prize for Research in Pick's, Alzheimer's, and Related Diseases
Sponsored by the American Academy of Neurology and the AAN Foundation and funded through the philanthropy of the Potamkin Foundation.

This award recognizes major contributions to the understanding of the causes, prevention, treatment, and cure for Pick's, Alzheimer's, and related diseases.

Presentation
Recipient is expected to present a 20-minute lecture during an aging and dementia scientific session at the 61st AAN Annual Meeting.

Recipient will receive:

Medallion and $100,000 prize
Complimentary registration for 61st Annual Meeting
Recognition at 2009 Awards Luncheon at 61st Annual Meeting
Eligibility
Must be in any of the following biological disciplines: neurology, neuropathology, biochemistry, molecular biology, molecular genetics, chemistry, pharmacology, immunology, physiology, or cell biology

Application Procedure

Applicants should submit one complete set of the following materials:

Completed application form
Current curriculum vitae
Letter citing scientific accomplishments in detail
Two recommendation letters
Up to six selected reprints

Deadline

The deadline to apply for 2009 AAN Scientific Awards is November 3, 2008. Applications will be available in August 2008.

For more information, please contact Erin Jackson at ejackson@aan.com or (651) 695-2704.

Medical Research Grants and Postdoctoral Fellowships Offered for Studies Aimed at Treatment of Fragile X

INTRODUCTION

The FRAXA Research Foundation offers a grants and fellowships program designed to encourage research aimed at finding a specific treatment for fragile X syndrome.

Fellowships of up to $40,000 per year will be offered to support postdoctoral fellows who want to pursue research in fragile X (salary plus fringe benefits and/or travel to meetings).
FRAXA also invites investigator-initiated research applications for innovative pilot studies aimed at developing and characterizing new therapeutic approaches for the treatment and ultimate cure of fragile X syndrome. There is no funding limit to this category of grant, but typical funding levels are $30K - 60K.
FRAXA is particularly interested in preclinical studies of potential pharmaceutical and genetic treatments and studies aimed at understanding the function of the FMR1 gene. New applications are accepted each year on February 1. If February 1 falls on a Saturday or Sunday, the deadline will be the following Monday.

Fellowships and grants are generally awarded for a period of one year. Based on reasonable progress during that year, awards may be renewable for a second year. Renewal applications are due on February 1, at least three months before the second year of funding is needed. If February 1 falls on a Saturday or Sunday, the deadline will be the following Monday.

PURPOSE OF GRANTS/FELLOWSHIPS

The purpose of this grant program is to promote research aimed at finding a specific treatment for fragile X syndrome. FRAXA's goal is to bring practical treatment into current medical practice as quickly as possible; therefore, preference will be given to research projects that have a clear practical application and the results of which will be shared with other qualified researchers in a timely fashion.

ELIGIBILITY FOR GRANTS/FELLOWSHIPS

Institutions receiving grants must be recognized as nonprofit. In the US, this means that institutions are exempt from federal income taxes. Preference is given to institutions within the United States.

Individuals nominated by applicant institutions for the postdoctoral fellowship should have training and experience at least equal to the Ph.D. or M.D. Level. Preference is given to United States citizens.

ACCEPTABLE COSTS

Acceptible costs covered by FRAXA postdoctoral fellowships and investigator-initiated awards are limited to:

Postdoctoral salary
Fringe benefits
A budget for consumable supplies
FRAXA reserves the right to cover any item if explicitly authorized by FRAXA's Board of Directors. However, FRAXA is unable to pay for indirect costs under any circumstances.

Fellowships and grants are awarded for the period of one year and may be renewed for a second year, based on satisfactory progress. A financial report and progress report are required at the end of each year.

AMENDMENT OF POLICIES

The FRAXA Research Foundation reserves the right to modify its policies governing grants at any time. The grantee agrees to abide by any changes or to terminate the grant at the time when such changes become effective. Failure to abide by the policies governing grants shall be considered sufficient grounds for cancellation of a grant or refusal to consider any pending application by the grantee.

PROHIBITION OF DISCRIMINATION

No person shall be excluded from participation in or denied the benefits of any program or activity receiving financial assistance from FRAXA because of race, ethnic origin, religion, sex, or sexual orientation.

HUMAN AND ANIMAL SUBJECTS

Human subjects studied in the course of research conducted under a grant are under no circumstances a responsibility of FRAXA. Human subjects in a program supported by FRAXA shall be volunteers in any survey, study or procedure. Research involving human subjects must have Institutional Review Board approval.

If animals are used in the proposed study, written certification must be provided to FRAXA indicating that proper treatment, care, and humane conditions have been provided. Research involving animal subjects must have Institutional Animal Care and Use Committee approval.

OBLIGATIONS OF THE GRANTEE

In accepting a grant, the applying institution undertakes that at its conclusion it will

Submit promptly to FRAXA a complete final report on the work pursued.
On awards of more than one year duration, a yearly report will be expected.
Supply an accounting of funds received from FRAXA and expenditures made in such detail and in such manner as may meet Internal Revenue Service procedures.
Recognize the support of FRAXA in any published article resulting from the work pursued with a credit line reading "Supported in part by a grant from the FRAXA Research Foundation"
Recognize the support of FRAXA in any presentation of the at professional meetings and conferences.

PUBLICATION AND DISSEMINATION OF RESULTS

FRAXA's purpose in providing grants is to speed up progress towards treatment for fragile X. Therefore, in accepting an award, the Principal Investigator undertakes to publish the results of the work pursued in the primary literature, in a timely fashion. Once published, the reagents, methods, materials, and products of the work must be made available to other qualified researchers. FRAXA reserves the right to share in any proceeds from an invention or discovery developed under this grant, including licensing fees and patent rights.

PUBLICITY ON WORK UNDER GRANT

The grantee institution and Principal Investigator will cooperate fully with FRAXA in announcement through the news media of grants awarded and in materials prepared to publicize work under the grant. FRAXA will publish periodic descriptions and updates on funded projects in its quarterly members' newsletter.

APPLICATION PROCESS

Potential applicants are encouraged to submit a brief letter of inquiry describing the proposed project before writing a full application. No specific application format is required, but an NIH R01 proposal is acceptable.

Please provide the following information with your application:

Description of the proposed project (6-12 pages recommended)
Curriculum Vitae for the Principal Investigator
Curriculum Vitae for the Postdoctoral Fellow to be supported under the grant
Names of 3 references who are willing to be contacted to provide recommendations for candidate postdoctoral fellow (not necessary for principal investigators)
Financial accounting of how the funds will be spent, with dollar distribution into major component items
A full accounting of any other current and submitted sources of support for this project and other lab research
Requested start date of the project. The earliest possible start date is 3 months after receipt of the application; applicants will be notified of awards in 2 months.
Send one complete copy of the application by email to fraxa@comcast.net, as an attached file in Acrobat PDF format. Alternately, this electronic copy may be sent to the address below on a CD. Also please send one copy of the application to:

Michael Tranfaglia, MD
Medical Director
FRAXA Research Foundation
45 Pleasant St. Second Floor
Newburyport, MA 01950

Applications must be postmarked by the deadline date.

RENEWALS

FRAXA grants are awarded for a single year and are generally renewable, based on good progress being made the first year. We require a renewal application be submitted by FRAXA's regular deadline (February 1). The renewal application should consist of a detailed progress report for the first year and work plan for the second year, as well as a financial report of how first year funds were spent.

For further information contact Michael Tranfaglia at FRAXA
Phone (978) 462-1866
Fax: (978) 463-9985

Targeted Research Initiative for Seniors
Application Deadline: March 2, 2009
Award Amount: up to $100,000 for one year
Program information and instructions available Fall 2008
The Targeted Research Initiative for Seniors is looking for interested investigators to conduct pilot research in the fundamental knowledge of aging and epilepsy; diagnosis of partial seizures; and epilepsy therapeutics in the elderly. Investigators must hold a relevant advanced degree (M.D. and/or Ph.D.) and have completed all research training.

Applicants may request up to $100,000 for one year. Grants awarded for higher than $50,000 per year are based on funds available and may be offered if the applicant proposes particularly meritorious work and has provided clear justification based on need and timetable of the work proposed.

Epilepsy Foundation of America 8301 Professional Place Landover MD 20785 (800) 332 1000

Announcement & Request for nominations

Honors & Awards of the American College of Clinical Pharmacology

The College's Honors & Awards Committee makes recommendations to the Board of Regents on awards, based upon nominations received from the membership. The College cordially invites nominations for all awards from ACCP members, fellows, and, in the case of the McKeen Cattell Award, from all interested readers of the Journal of Clinical Pharmacology.

All awards consist of an appropriately inscribed certificate or plaque, and payment of all expenses incurred in connection with attendance at the awards ceremony during the annual meeting. In addition, the Tanabe Young Investigator and McKeen Cattell Memorial Awards carry honoraria of $1000 each. With the exception of the McKeen Cattell Award and Tanabe Young Investigator Award, each awardee is expected to give an approximately 20-30 minute address on a subject related to the basis for the award and to submit a short manuscript based on the talk, as suitable for publication in the Journal of Clinical Pharmacology.

Materials Requested: Nominations should consist of a detailed letter summarizing the individual's accomplishments or major basis for the nomination or specific reasons for selecting a particular Journal of Clinical Pharmacology publication in the case of the McKeen Cattell award.

All nominations should be sent by December 31, 2008 to:

Chairman, Honors and Awards Committee
American College of Pharmacology
3 Ellinwood Court
New Hartford, NY 13413-1105
Alternatively, nominations can be submitted via email to: Susan Ulrich